KY02111

WNT pathway inhibitor

More Views

KY02111

WNT pathway inhibitor

5 mg
Catalog #72582
104 USD

Overview

KY02111 promotes the differentiation of pluripotent stem cells (PSCs) to cardiomyocytes by inhibiting canonical WNT signaling in a manner distinct from that of other WNT inhibitors (Minami et al.).

DIFFERENTIATION
· Promotes cardiomyocyte differentiation of human and mouse PSCs in combination with BIO, CHIR99021, and XAV939 (Minami et al.).
Alternative Names:
Not applicable
CAS Number:
1118807-13-8
Chemical Formula:
C₁₈H₁₇ClN₂O₃S
Molecular Weight:
376.9 g/mol
Purity:
≥ 95%
Pathway:
WNT

Scientific Resources

Product Documentation

Document Type
Product Name
Catalog #
Lot #
Language

Educational Materials

(3)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Publications

(1)
Cell reports 2012 NOV

A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine- and xeno-free conditions.

Minami I et al.

Abstract

Human pluripotent stem cells (hPSCs), including embryonic stem cells and induced pluripotent stem cells, are potentially useful in regenerative therapies for heart disease. For medical applications, clinical-grade cardiac cells must be produced from hPSCs in a defined, cost-effective manner. Cell-based screening led to the discovery of KY02111, a small molecule that promotes differentiation of hPSCs to cardiomyocytes. Although the direct target of KY02111 remains unknown, results of the present study suggest that KY02111 promotes differentiation by inhibiting WNT signaling in hPSCs but in a manner that is distinct from that of previously studied WNT inhibitors. Combined use of KY02111 and WNT signaling modulators produced robust cardiac differentiation of hPSCs in a xeno-free, defined medium, devoid of serum and any kind of recombinant cytokines and hormones, such as BMP4, Activin A, or insulin. The methodology has potential as a means for the practical production of human cardiomyocytes for regeneration therapies.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.